US FDA Taps Abernethy As Principal Deputy Commissioner; Health IT Exec Brings “Real-World” Expertise
Executive Summary
Abernethy comes to FDA from Flatiron Health, which develops oncology-specific electronic health record software and real-world evidence for cancer research. She succeeds FDA veteran Rachel Sherman, who will retire from the agency in January.
You may also be interested in...
Abernethy’s Departure From US FDA Gives Next Commissioner Options For A New Number Two
Janet Woodcock has been in the lead in the commissioner race for months without an announcement, but now serious doubts are being cast on her candidacy, including the tone of remarks at a White House press briefing.
US FDA’s Abernethy Leaves Behind Legacy Of Tech Modernization, Real-World Data
After slightly more than two years as second-in-command, Abernethy says she’s leaving FDA because her initiatives were starting to develop their own momentum. Abernethy, who the agency’s acting chief information officer, worked to modernize FDA’s information technology infrastructure and data capabilities while also exploring confidently using real-world data to support regulatory decision-making.
US FDA’s Amy Abernethy Leaves Behind Legacy Of Tech Modernization, Real-World Data
After slightly more than two years as second-in-command, Abernethy tells the Pink Sheet she’s leaving FDA because the initiatives on which she was focused were starting to develop their own momentum. Abernethy, who also serves as the agency’s acting chief information officer, worked to modernize the FDA’s information technology infrastructure and data capabilities while also exploring ways to confidently use real-world data to support regulatory decision-making.